Aviv Clinics Spotlights New Study Using Hyperbaric Oxygen Therapy for Adults Suffering from Fibromyalgia Related to Childhood Sexual Abuse
28 mai 2024 09h00 HE
|
Aviv Clinics
ORLANDO, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Aviv Clinics, one of the world’s most advanced brain treatment centers, shared the results of a new study which shows hyperbaric oxygen therapy (HBOT)...
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
22 mai 2024 13h30 HE
|
Virios Therapeutics
ATLANTA, May 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel...
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
19 mai 2024 20h53 HE
|
Virios Therapeutics
ATLANTA, May 19, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel...
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 07h45 HE
|
Virios Therapeutics
- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 - - Conference Call...
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
02 mai 2024 09h15 HE
|
Virios Therapeutics
ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
26 mars 2024 09h15 HE
|
Virios Therapeutics
- New patent would extend coverage and expand potential value of Virios’ antiviral pipeline globally – - Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses...
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
29 févr. 2024 09h15 HE
|
Virios Therapeutics
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
28 févr. 2024 09h15 HE
|
Virios Therapeutics
ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
15 févr. 2024 08h45 HE
|
FN Media Group LLC
PALM BEACH, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Numerous reports indicate that the fibromyalgia treatment market is positioned to continue to grow at a...
Fibromyalgia Treatment Market Projected to Surpass US$ 2.7 Billion in Revenue by 2033, According to Persistence Market Research
18 janv. 2024 09h45 HE
|
Persistence Market Research
New York, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Market Overview: The global revenue from the fibromyalgia treatment market stands at US$ 1.3 billion in 2022, with the global market expected to grow...